The first approved broad RAS-targeting approach in pancreatic cancer nearly doubled overall survival versus chemotherapy.
Key Takeaways
- The FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
- In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with Rasonque versus 6.7 months with standard chemotherapy.
- Daraxonrasib targets multiple active RAS variants rather than a single KRAS mutation, potentially extending RAS-targeted therapy to a much broader pancreatic cancer population.
Data Snapshot
| Item | Details |
|---|---|
| Drug | Rasonque (daraxonrasib) |
| Company | Revolution Medicines |
| Mechanism | Oral RAS(ON) multi-selective inhibitor |
| FDA-approved indication | Metastatic pancreatic adenocarcinoma |
| Treatment setting | After ≥1 prior systemic therapy or when multiagent therapy is inappropriate |
| Pivotal trial | Phase 3 RASolute 302 |
| Trial population | 500 patients |
| Median OS | 13.2 vs 6.7 months |
| Median PFS | 7.2 vs 3.6 months |
| ORR | 30% vs 11% |
| Recommended dose | 300 mg once daily |
Rasonque significantly improved overall survival, progression-free survival and objective response rate compared with standard-of-care chemotherapy in the overall trial population.
What Happened
The U.S. Food and Drug Administration approved Revolution Medicines’ Rasonque (daraxonrasib) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. This is the first FDA approval for daraxonrasib.
Reuters described the approval as a major advance for pancreatic cancer, a disease in which targeted treatment options have historically been limited. Rasonque is a once-daily oral therapy designed to inhibit multiple forms of RAS, one of the central oncogenic drivers in pancreatic adenocarcinoma. (Reuters article)
The FDA separately described Rasonque as a first-in-class targeted therapy for metastatic pancreatic cancer. According to the agency, the drug targets multiple forms of RAS and provides a new treatment option for patients with advanced pancreatic cancer. (FDA press announcement)
Approval was based on the randomized, open-label Phase 3 RASolute 302 trial (NCT06625320), which enrolled 500 patients with metastatic pancreatic adenocarcinoma whose disease had progressed after one prior line of systemic therapy.
In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard-of-care chemotherapy, corresponding to a hazard ratio of 0.40. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% versus 11%. (FDA clinical approval details)
Revolution Medicines describes Rasonque as the first broad RAS-targeted medicine in metastatic pancreatic cancer. The company also emphasized that the FDA-approved indication applies to patients with or without an identified RAS tumor mutation and does not require a companion diagnostic test. (Revolution Medicines announcement)
Why It Matters
Pancreatic ductal adenocarcinoma is one of the cancers most strongly driven by RAS signaling. More than 90% of pancreatic ductal adenocarcinomas are driven by mutant KRAS, making RAS an especially important therapeutic target in this disease.
The first generation of successful KRAS inhibitors focused largely on individual mutations such as KRAS G12C. That approach proved that KRAS could be drugged, but G12C represents only a small fraction of pancreatic cancers.
Daraxonrasib takes a broader approach. It is a RAS(ON) multi-selective inhibitor designed to inhibit the active, GTP-bound state of RAS across multiple variants, including mutant and wild-type KRAS, NRAS and HRAS.
That distinction is clinically important because Rasonque does not require patients to carry one specific KRAS mutation. The FDA-approved indication also does not require a companion diagnostic, potentially allowing a wider population of metastatic pancreatic cancer patients to receive RAS-targeted therapy.
Want to understand how daraxonrasib targets active RAS and why RAS(ON) inhibition differs from mutation-specific KRAS inhibitors?
Read the BP Science explainer:
How Daraxonrasib Blocks Active RAS Across Multiple Mutations
BP View
Rasonque is important because it provides the first commercial validation that broad RAS inhibition can deliver a meaningful survival benefit in pancreatic cancer. Earlier mutation-specific KRAS inhibitors proved that KRAS itself could be drugged, but their use is naturally limited to patients carrying the corresponding mutation.
Daraxonrasib takes a different approach by targeting multiple active RAS variants. This gives Rasonque a clear advantage in terms of patient coverage, particularly in pancreatic cancer, where RAS alterations are common but distributed across several mutation subtypes.
However, broader coverage does not necessarily mean that broad RAS inhibition will ultimately become the dominant strategy. Mutation-specific inhibitors, particularly those targeting KRAS G12D, are advancing rapidly. Revolution Medicines itself is developing the G12D-selective inhibitor zoldonrasib in Phase 3, showing that the company is pursuing both broad and mutation-specific RAS strategies. (Revolution Medicines — Zoldonrasib has entered Phase 3 development for first-line RAS G12D pancreatic cancer.)
In my view, this creates the more interesting long-term competition. Broad RAS inhibitors offer wider patient access, while mutation-specific inhibitors may ultimately provide greater precision, efficacy or tolerability. Rasonque has taken the lead by validating the broad approach, but the next stage of RAS-targeted therapy will likely be defined by whether broad coverage or mutation-specific precision produces the better clinical outcome.
Related Post
For another recent example of a targeted oncology therapy expanding treatment options, read my previous analysis of Jazz Pharmaceuticals’ first-line FDA approval for Ziihera in HER2-positive gastroesophageal cancer.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Leave a Reply